Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure
Mechanisms and Clinical Applications: A Machine-Generated Literature Overview
Buch in deiner Nähe kaufen
Beschreibung
The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
The book delves into the development and therapeutic potential of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of diabetes and cardiovascular diseases. It explores their mechanism of action, cardiovascular benefits, and role in primary and secondary protection from renal and cardiovascular diseases. The book also highlights their emerging opportunities in the management of myocardial infarction, diabetic cardiomyopathy, and congestive heart failure. It provides a comprehensive review of preclinical and clinical information on the cardiovascular advantages of SGLT2 inhibitors. Additionally, the book explores selective drugs and their effects on cardiovascular events, mortality, and safety outcomes in individuals with type 2 diabetes.
The book is a valuable resource for researchers, healthcare professionals, and individuals interested in the field of SGLT2 inhibitors and their impact on diabetes and cardiovascular health.
A Machine-Generated Literature Overview of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Delves into SGLT2 inhibitors' role in preventing cardiovascular and renal diseases in diabetes Explores potential of SGLT2 inhibitors in preventing diabetic cardiomyopathy & managing congestive heart failure
Autor*in
Mukesh Nandave
Themen in »Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure«
SGLT2 inhibitors in type 2 diabetes Mechanisms of SGLT2 inhibitors for cardiovascular benefits Myocardial infarction SGLT2 inhibitors in cardiovascular outcomes Congestive heart failure